2025 ABC International Dr. Jay Brown Abstract Competition | June 28
The Association of Black Cardiologists (ABC), supported, in part, by Amgen [...]
Amgen Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
MariTide Demonstrated up to ~20% Average Weight Loss at 52 [...]
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
– Attruby is the first and only approved product with a [...]
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Acoramidis demonstrated the earliest known time to separation in cardiovascular [...]